Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 5/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 4/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.46 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7138968 | 0.85 | MAPT (0.49) | FLT3MEN1KMT2ARPS6KA3KDR | |
| SCHEMBL1388519 | 0.85 | RET (0.54) | FLT3MEN1KMT2ARPS6KA3EGFR | |
| SCHEMBL1388393 | 0.85 | PDPK1 (0.54) | FLT3MEN1KMT2AKDREGFR | |
| SCHEMBL13080589 | 0.85 | LRRK2 (0.61) | RPS6KA3PDGFRBMDM2 | |
| SCHEMBL7874137 | 0.84 | GSK3B (0.59) | FLT3MEN1KMT2ARPS6KA3KDR | |
| SCHEMBL8291555 | 0.84 | GSK3B (0.59) | FLT3MEN1KMT2ARPS6KA3KDR | |
| SCHEMBL1388800 | 0.82 | TLK2 (0.57) | MEN1KMT2AKDREGFRCSF1R | |
| SCHEMBL13080905 | 0.81 | GSK3B (0.67) | MEN1KMT2APDGFRBCDK2CCNE1 | |
| SCHEMBL7132958 | 0.81 | PDGFRB (0.43) | MEN1KMT2ARPS6KA3EGFRCSF1R | |
| SCHEMBL7138017 | 0.79 | SRC (0.52) | KDREGFRCSF1RPDGFRBKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298376-A1 | USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298376-A1 | USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | NLN, HTT, PARK7 | FLT3 3095/4885MEN1 3621/4885KMT2A 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.